Medifast Inc MED.N, MED is expected to show a fall in quarterly revenue when it reports results on February 18 for the period ending December 31 2024
The Baltimore Maryland-based company is expected to report a 40.2% decrease in revenue to $114.25 million from $191.02 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on November 4 2024, for the period ended December 31, was for revenue between $100.00 million and $120.00 million.
LSEG's mean analyst estimate for Medifast Inc is for a loss of 16 cents per share. The company's EPS guidance on November 4 2024, for the period ended December 31, was between $-0.65 and $-0.10
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Medifast Inc is $16.50, above its last closing price of $16.03.
This summary was machine generated February 14 at 21:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.